Secreted proteins as a fundamental source for biomarker discovery

Proteomics

Volumn 12, Issue 4-5, 2012, Pages 722-735

  Stastna, Miroslava ^a,b   Van Eyk, Jennifer E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INSTITUTE OF ANALYTICAL CHEMISTRY   (Czech Republic)

Author keywords

Biomarker discovery; Biomedicine; Conditioned media; Secreted proteins

Indexed keywords

ADRENOMEDULLIN; ALPHA 2 MACROGLOBULIN; ATRIOPEPTIGEN; BIOLOGICAL MARKER; CARBOXYPEPTIDASE; CASEIN ALPHAS1; CAT EYE SYNDROME CRITICAL REGION PROTEIN 1; CD163 ANTIGEN; CD59 ANTIGEN; CLUSTERIN; CONNECTIVE TISSUE GROWTH FACTOR; CYSTATIN M; DECTIN 1; DEOXYRIBONUCLEASE I; DKK3 PROTEIN; EGF CONTAINING FIBULIN LIKE ECM PROTEIN 1; EGF LIKE REPEAT AND DISCOIDIN I LIKE DOMAIN CONTAINING PROTEIN 3; ENDOSIALIN; FIBRINOGEN ALPHA; FIBRINOGEN GAMMA; GAMMA INTERFERON INDUCIBLE LYSOMAL THIOL REDUCTASE PROTEIN; GELSOLIN; HAPTOGLOBIN; HEMOPEXIN; HISTIDINE RICH GLYCOPROTEIN; LAMININ RECEPTOR; PROGRANULIN; PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AMINO ACID SEQUENCE; CARDIOVASCULAR DISEASE; CELL CULTURE; CELL FRACTIONATION; CELL TYPE; CULTURE MEDIUM; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; HEART MUSCLE CELL; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN SECRETION; REVIEW; SMOOTH MUSCLE FIBER;

ANIMALS; BLOOD PROTEINS; ENDOTHELIAL CELLS; HUMANS; MUSCLE, SMOOTH; MYOCYTES, CARDIAC; NEOPLASM PROTEINS; PROTEINS; PROTEOMICS; RATS; STEM CELLS; TUMOR MARKERS, BIOLOGICAL;

RATTUS;

EID: 84859220149     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201100346     Document Type: Review

References (119)

1. Makridakis, M., Vlahou, A., Secretome proteomics for discovery of cancer biomarkers. J. Proteomics 2010, 73, 2291-2305.
2. Doroudgar, S., Glembotski, C. C., The cardiokine story unfolds: ischemic stress-induced protein secretion in the heart. Cell 2011, 17, 207-214.
3. Celis, J. E., Gromov, P., Cabezon, T., Moreira, J. M. et al., Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery. Mol. Cell. Proteomics 2004, 3, 327-344.
4. Gromov, P., Gromova, I., Bunkenborg, J., Cabezon, T. et al., Up-regulated proteins in the fluid bathing the tumour cell microenvironment as potential serological markers for early detection of cancer of the breast. Mol. Oncol. 2010, 4, 65-89.
5. He, J., Gornbein, J., Shen, D., Lu, M. et al., Detection of breast cancer biomarkers in nipple aspirate fluid by SELDI-TOF and their identification by combined liquid chromatography-tandem mass spectrometry. Int. J. Oncol. 2007, 30, 145-154.
6. Varnum, S. M., Covington, C. C., Woodbury, R. L., Petritis, K. et al., Proteomic characterization of nipple aspirate fluid: identification of potential biomarkers of breast cancer. Breast Cancer Res. Treat. 2003, 80, 97-97.
7. Raimondo, F., Morosi, L., Chinello, C., Magni, F. et al., Advances in membranous vesicle and exosome proteomics improving biological understanding and biomarker discovery. Proteomics 2011, 11, 709-720.
8. Dowling, P., Clynes, M., Conditioned media from cell lines: A complementary model to clinical specimens for the discovery of disease-specific biomarkers. Proteomics 2011, 11, 794-804.
9. Surinova, S., Schiess, R., Huttenhain, R., Cerciello, F. et al., On the development of plasma protein biomarkers. J. Proteome Res. 2011, 10, 5-16.
10. Van Eyk, J. E., Overview: The maturing of proteomics in cardiovascular research. Circ. Res. 2011, 108, 490-498.
11. Suzuki, T., Tsuruda, A., Katoh, S., Kubodera, A. et al., Purification of endothelin from conditioned medium of cardiac fibroblastic cells using beating rate assay of myocytes cultured in a serum-free medium. J. Mol. Cell. Cardiol. 1997, 29, 2087-2093.
12. Xu, X. Q., Graichen, R., Soo, S. Y., Balakrishnan, T. et al., Chemically defined medium supporting cardiomyocyte differentiation of human embryonic stem cells. Differentiation 2008, 76, 958-970.
13. Stastna, M., Chimenti, I., Marbán, E., Van Eyk, J. E., Identification and functionality of proteomes secreted by rat cardiac stem cells and neonatal cardiomyocytes. Proteomics 2010, 10, 245-253.
14. Xu, R. X., Chen, J. H., Han, Y., Han, B. M., Mesenchymal stem cells promote cardiomyocyte hypertrophy in vitro through hypoxia-induced paracrine mechanisms. Clin. Exp. Pharmacol. Physiol. 2009, 36, 176-180.
15. Maxeiner, H., Krehbiehl, N., Muller, A., Woitasky, N. et al., New insights into paracrine mechanisms of human cardiac progenitor cells. Eur. J. Heart Fail. 2010, 12, 730-737.
16. Julka, S., Regnier, F., Quantification in proteomics through stable isotope coding: a review. J. Proteome Res. 2004, 3, 350-363.
17. Ong, S. E., Blagoev, B., Kratchmarova, I., Kristensen, D. B. et al., Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell. Proteomics 2002, 1, 376-386.
18. Lange, V., Picotti, P., Domon, B., Aebersold, R., Selected reaction monitoring for quantitative proteomics: a tutorial. Mol. Syst. Biol. 2008, 4, 222.
19. Stastna, M., Van Eyk, J. E., Investigating the secretome: Lessons about the cells that comprise the heart. Circ. Cardiovasc. Genetics 2012, 5, (in press).
20. Dupont, A., Corseaux, D., Dekeyzer, O., Drobecq, H. et al., The proteome and secretome of human arterial smooth muscle cells. Proteomics 2005, 5, 585-596.
21. Dupont, A., Pinet, F., The proteome and secretome of human arterial smooth muscle cell. Methods Mol. Biol. 2007, 357, 225-233.
22. Liao, D., Jin, Z., Baas, A. S., Daum, G. et al., Purification and identification of secreted oxidative stress-induced factors from vascular smooth muscle cells. J. Biol. Chem. 2000, 275, 189-196.
23. Qi, Y., Jiang, J., Jiang, X., Wang, X. et al., PDGF-BB and TGF-β1 on cross-talk between endothelial and smooth muscle cells in vascular remodeling induced by low shear stress. Proc. Natl. Acad. Sci. USA 2011, 108, 1908-1913.
24. Kado, M., Lee, J. K., Hidaka, K., Miwa, K. et al., Paracrine factors of vascular endothelial cells facilitate cardiomyocyte differentiation of mouse embryonic stem cells. Biochem. Biophys. Res. Commun. 2008, 377, 413-418.
25. Bruneel, A., Labas, V., Mailloux, A., Sharma, S. et al., Proteomics of human umbilical vein endothelial cells applied to etoposide-induced apoptosis. Proteomics 2005, 5, 3876-3884.
26. Scheurer, S. B., Rybak, J. N., Rosli, C., Neri, D., Elia, G., Modulation of gene expression by hypoxia in human umbilical cord vein endothelial cells: A transcriptomic and proteomic study. Proteomics 2004, 4, 1737-1760.
27. Urbich, C., De Souza, A. I., Rossig, L., Yin, X. et al., Proteomic characterization of human early pro-angiogenic cells. J. Mol. Cell. Cardiol. 2011, 50, 333-336.
28. Tunica, D. G., Yin, X., Sidibe, A., Stegemann, C. et al., Proteomic analysis of the secretome of human umbilical vein endothelial cells using a combination of free-flow electrophoresis and nanoflow LC-MS/MS. Proteomics 2009, 9, 4991-4996.
29. Simper, D., Mayr, U., Urbich, C., Zampetaki, A. et al., Comparative proteomics profiling reveals role of smooth muscle progenitors in extracellular matrix production. Arterioscler. Thromb. Vasc. Biol. 2010, 30, 1325-1332.
30. Asahara, T., Murohara, T., Sullivan, A., Silver, M. et al., Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275, 964-967.
31. Koiwaya, H., Sasaki, K., Ueno, T., Yokoyama, S. et al., Augmented neovascularization with magnetized endothelial progenitor cells in rats with hind-limb ischemia. J. Mol. Cell. Cardiol. 2011, 51, 33-40.
32. Urbich, C., Heeschen, C., Aicher, A., Sasaki, K. et al., Cathepsin L is required for endothelial progenitor cell-induced neovascualrization. Nat. Med. 2005, 11, 206-213.
33. Oh, H., Bradfute, S. B., Gallardo, T. D., Nakamura, T. et al., Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc. Natl. Acad. Sci. USA 2003, 100, 12313-12318.
34. Urbanek, K., Quaini, F., Tasca, G., Torella, D. et al., Intense myocyte formation from cardiac stem cells in human cardiac hypertrophy. Proc. Natl. Acad. Sci. USA 2003, 100, 10440-10445.
35. Beltrami, A. P., Barlucchi, L., Torella, D., Baker, M. et al., Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 2003, 114, 763-776.
36. Messina, E., De Angelis, L., Frati, G., Morrone, S. et al., Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ. Res. 2004, 95, 911-921.
37. Linke, A., Muller, P., Nurzynska, D., Casarsa, C. et al., Stem cells in the dog heart are self-renewing, clonogenic, and multipotent and regenerate infarcted myocardium, improving cardiac function. Proc. Natl. Acad. Sci. USA 2005, 102, 8966-8971.
38. Tillmanns, J., Rota, M., Hosoda, T., Misao, Y. et al., Formation of large coronary arteries by cardiac progenitor cells. Proc. Natl. Acad. Sci. USA 2008, 105, 1668-1673.
39. Angert, D., Berretta, R. M., Kubo, H., Zhang, H. et al., Repair of the injured adult heart involves new myocytes potentially derived from resident cardiac stem cells. Circ. Res. 2011, 108, 1226-1237.
40. Chimenti, I., Smith, R. R., Li, T. S., Gerstenblith, G., Messina, E. et al., Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infracted mice. Circ. Res. 2010, 106, 971-980.
41. Stastna, M., Abraham, M. R., Van Eyk, J. E., Cardiac stem/progenitor cells, secreted proteins, and proteomics. FEBS Lett. 2009, 583, 1800-1807.
42. Maltais, S., Tremblay, J. P., Perrault, L. P., Ly, H. Q., The paracrine effect: pivotal mechanism in cell-based cardiac repair. J. Cardiovasc. Transl. Res. 2010, 3, 652-662.
43. Naito, H., Melnychenko, I., Didié, M., Schneiderbanger, K. et al., Optimizing engineered heart tissue for therapeutic applications as surrogate heart muscle. Circulation 2006, 114, I72-I78.
44. Zakharova, L., Mastroeni, D., Mutlu, N., Molina, M. et al., Transplantation of cardiac progenitor cell sheet onto infarcted heart promotes cardiogenesis and improves function. Cardiovasc. Res. 2010, 87, 40-49.
45. Morrison, S. J., Sprading, A. C., Stem cells and niches: Mechanisms that promote stem cell maintenance throughout life. Cell 2008, 132, 598-611.
46. Laflamme, M. A., Murry, C. E., Heart regeneration. Nature 2011, 473, 326-335.
47. Ye, Z., Zhou, Y., Cai, H., Tan, W., Myocardial regeneration: Roles of stem cells and hydrogels. Adv. Drug Deliv. Rev. 2011, 63, 688-697.
48. Gaetani, R., Rizzitelli, G., Chimenti, I., Barile, L., et al., Cardiospheres and tissue engineering for myocardial regeneration: potential for clinical application. J. Cell Mol. Med. 2010, 14, 1071-1077.
49. Bersell, K., Arab, S., Haring, B., Kuhn, B., Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell 2009, 138, 257-270.
50. Smith, R. R., Barile, L., Cho, H. C., Leppo, M. K. et al., Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimen. Circulation 2007, 115, 896-908.
51. Farrah, T., Deutsch, E. W., Omenn, G. S., Campbell, D. S. et al., A high-confidence human plasma proteome reference set with estimated concentrations in PeptideAtlas. Mol. Cell. Proteomics 2011 [Epub ahead of print; Manuscript M110. 006353].
52. Xue, H., Lu, B., Lai, M., The cancer secretome: a reservoir of biomarkers. J. Transl. Med. 2008, 6, 52.
53. Huang, C. M., Ananthaswamy, H. N., Barnes, S., Ma, Y. et al., Mass spectrometric proteomics profiles of in vivo tumor secretomes: capillary ultrafiltration sampling of regressive tumor masses. Proteomics 2006, 6, 6107-6116.
54. Huang, C. M., Wang, C. C., Kawai, M., Barnes, S. et al., In vivo protein sampling using capillary ultrafiltration semi-permeable hollow fiber and protein identification via mass spectrometry-based proteomics. J. Chromatogr. A 2006, 1109, 144-151.
55. Yang, S., Huang, C. M., Recent advances in protein profiling of tissues and tissue fluids. Expert Rev. Proteomics 2007, 4, 515-529.
56. Bakota, E. L., Wang, Y., Danesh, F. R., Hartgerink, J. D., Injectable multidomain peptide nanofiber hydrogel as a delivery agent for stem cell secretome. Biomacromolecules 2011, 12, 1651-1657.
57. Wang, Y., Bakota, E., Chang, B. H., Entman, M. et al., Peptide nanofibers preconditioned with stem cell secretome are renoprotective. J. Am. Soc. Nephrol. 2011, 22, 704-717.
58. Kisiday, J., Jin, M., Kurz, B., Hung, H. et al., Self-assembling peptide hydrogel fosters chondrocyte extracellular matrix production and cell division: implications for cartilage tissue repair. Proc. Natl. Acad. Sci. USA 2002, 99, 9996-100001.
59. Chiu, L. L., Radisic, M., Vunjak-Novakovic, G., Bioactive scaffolds for engineering vascularized cardiac tissue. Macromol. Biosci. 2010, 10, 1286-1301.
60. Sarig, U., Machluf, M., Engineering cell platforms for myocardial regeneration. Expert Opin. Biol. Ther. 2011, 11, 1055-1077.
61. Branco, M. C., Schneider, J. P., Self-assembling materials for therapeutic delivery. Acta Biomater. 2009, 5, 817-831.
62. Hosseinkhani, H., Hosseinkhani, M., Khademhosseini, A., Kobayashi, H., Bone regeneration through controlled release of bone morphogenetic genetic protein-2 from 3-D tissue engineered nanoscaffold. J. Control. Release 2007, 117, 380-386.
63. Webber, M. J., Han, X., Prasanna Murthy, S. N., Rajangam, K. et al., Capturing the stem cell paracrine effect using heparin-presenting nanofibres to treat cardiovascular diseases. J. Tissue Eng. Regener. Med. 2010, 4, 600-610.
64. Berhane, B. T., Zong, C., Liem, D. A., Huang, A. et al., Cardiovascular-related proteins identified in human plasma by the HUPO Plasma Proteome Project Pilot Phase. Proteomics 2005, 5, 3520-3530.
65. Anderson, L., Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J. Physiol. 2005, 563, 23-60.
66. Moshage, H., Cytokines and the hepatic acute phase response. J. Pathol. 1997, 181, 257-266.
67. Luchtefeld, M., Preuss, C., Ruhle, F., Bogalle, E. P. et al., Gp130-dependent release of acute phase proteins is linked to the activation of innate immune signaling pathways. PLOS One 2011, 6, e19427.
68. Aebersold, R., Anderson, L., Caprioli, R., Druker, B. et al., Perspective: A program to improve protein biomarker discovery for cancer. J. Proteome Res. 2005, 4, 1104-1109.
69. Polanski, M., Anderson, N. L., A list of candidate cancer biomarkers for targeted proteomics. Biomarker Insights 2007, 1, 1-48.
70. Wu, C., Hsu, C., Chen, C., Yu, C. et al., Candidate serological biomarkers for cancer identified from the secretome of 23 cancer cell lines and the human protein atlas. Mol. Cell. Proteomics 2010, 9, 1100-1117.
71. Ristagno, G., Santonocito, C., Li, Y., Li Volti, G., Gullo, A., Biomarkers of myocardial injury after cardiac arrest or myocardial ischemia. Front Biosci. 2010, 2, 373-391.
72. Kataoka, Y., Miyazaki, S., Yasuda, S., Nagaya, N. et al., The first clinical pilot study of intravenous adrenomedullin administration in patients with acute myocardial infarction. J. Cardiovasc. Pharmacol. 2010, 56, 413-419.
73. Pavel, M. E., Hoppe, S., Papadopoulos, T., Linder, V. et al., Adrenomedullin is a novel marker of tumor progression in neuroendocrine carcinomas. Horm. Metab. Res. 2006, 38, 112-118.
74. Ramasamy, S., Omnath, R., Rathinavel, A., Kannan, P. et al., Cardiac isoform of α 2 macroglobulin, an early diagnostic marker for cardiac manifestations in AIDS patients. AIDS 2006, 20, 1979-1981.
75. Annapoorani, P., Dhandapany, P. S., Sadayappan, S., Ramasamy, S. et al., Cardiac isoform of α-2 macroglobulin - a new biomarker for myocardial infarcted diabetic patients. Atherosclerosis 2006, 186, 173-176.
76. Volpe, M., Francia, P., Tocci, G., Rubattu, S. et al., Prediction of long-term survival in chronic heart failure by multiple biomarker assessment: A 15-year prospective follow-up study. Clin. Cardiol. 2010, 33, 700-707.
77. Mitka, M., Researchers discover new biomarker that may improve cancer care strategies. J. Am. Med. Assoc. 2011, 305, 1184-1185.
78. Xu, K., Ling, M. T., Wang, X., Wong, Y. C., Evidence of a novel biomarker, α1-Casein, a milk protein, in benign prostate hyperplasia. Prostate Cancer Prostatic Dis. 2006, 9, 293-297.
79. Vakeva, A., Laurila, P., Meri, S., Loss of expression of protectin (CD59) is associated with complement membrane attack complex deposition in myocardial infarction. Lab Invest. 1992, 67, 608-616.
80. Watson, N. F., durrant, L. G., Madjd, Z., Ellis, I. O. et al., Expression of the membrane complement regulatory protein CD59 (protectin) is associated with reduced survival in colorectal cancer patients. Cancer Immunol. Immunother. 2006, 55, 973-980.
81. Trougakos, I. P., Poulakou, M., Stathatos, M., Chalikia, A. et al., Serum levels of the senescence biomarker clusterin/apolipoprotein J increase significantly in diabetes type II and during development of coronary heart disease or at myocardial infarction. Exp. Gerontol. 2002, 37, 1175-1187.
82. Miyake, H., Muramaki, M., Furukawa, J., Kurahashi, T. et al., Serum level of clusterin and its density in men with prostate cancer as a novel biomarkers reflecting disease extension. Urology 2010, 75, 454-459.
83. Koitabashi, N., Arai, M., Niwano, K., Watanabe, A. et al., Plasma connective tissue growth factor is a novel potential biomarker of cardiac dysfunction in patients with chronic heart failure. Eur. J. Heart Fail. 2008, 10, 373-379.
84. Lin, B. R., Chang, C. C., Che, T. F., Chen, S. T. et al., Connective tissue growth factor inhibits metastasis and acts as an independent prognostic marker in colorectal cancer. Gastroenterology 2005, 128, 9-23.
85. Werle, B., Sauckel, K., Nathanson, C. M., Bjarnadottir, M. et al., Cystatins C, E/M and F in human pleural fluids of patients with neoplastic and inflammatory lung disorders. Biol. Chem. 2003, 384, 281-287.
86. Arakawa, K., Kawai, Y., Kumamoto, T., Morokawa, N. et al., Serum deoxyribonuclease I activity can be used as a sensitive marker for detection of transient myocardial ischaemia induced by percutaneous coronary intervention. Eur. Heart 2005, 26, 2375-2380.
87. Yasuda, T., Kawai, Y., Ueki, M., Kishi, K., Clinical applications of DNase I, a genetic marker already used for forensic identification. Leg Med. 2005, 7, 274-277.
88. Fong, D., Hermann, M., Untergasser, G., Pirkebner, D. et al., Dkk-3 expression in the tumor endothelium: A novel prognostic marker of pancreatic adenocarcinomas. Cancer Sci. 2009, 100, 1414-1420.
89. Sadr-Nabavi, A., Ramser, J., Volkmann, J., Naehrig, J. et al., Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker. Int. J. Cancer 2009, 124, 1727-1735.
90. Sun, J. C., Liang, X. T., Pan, K., Wang, H. et al., High expression level of EDIL3 in HCC predicts poor prognosis of HCC patients. World J. Gastroenterol. 2010, 16, 4611-4615.
91. Raza-Ahmad, A., Fibrinogen: a diagnostic marker for early ischemia. Biotechnol. Histochem. 1994, 69, 268-272.
92. Polterauer, S., Grimm, C., Seebacher, V., Concin, N. et al., Plasma fibrinogen levels and prognosis in patients with ovarian cancer: a multicenter study. Oncologist 2009, 14, 979-985.
93. Liao, C. J., Wu, T. I., Huang, Y. H., Chang, T. C. et al., Overexpression of gelsolin in human cervical carcinoma and its clinicopathological significance. Gynecol. Oncol. 2011, 120, 135-144.
94. Pan, C. X., Kinch, M. S., Kiener, P. A., Langermann, S. et al., PC cell-derived growth factor expression in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. Clin. Cancer Res. 2004, 10, 1333-1337.
95. Shu, H., Kang, X., Guo, K., Li, S. et al., Diagnostic value of serum haptoglobin protein as hepatocellular carcinoma marker complementary to α fetoprotein. Oncol. Rep. 2010, 24, 1271-1276.
96. Xu, G., Hou, C. R., Jiang, H. W., Xiang, C. Q. et al., Serum protein profiling to identify biomarkers for small renal cell carcinoma. Indian J. Biochem. Biophys. 2010, 47, 211-218.
97. Qiu, Y., Patwa, T. H., Xu, L., Shedden, K. et al., Plasma glycoprotein profiling for colorectal cancer biomarker identification by lectin glycoarray and lectin blot. J. Proteome Res. 2008, 7, 1693-1703.
98. Hassfeld, S., Eichhorn, C., Stehr, K., Naegele, H. et al., Insulin-like growth factor-binding proteins 2 and 3 are independent predictors of a poor prognosis in patients with dilated cardiomyopathy. Heart 2007, 93, 359-360.
99. Liou, J. M., Shun, C. T., Liang, J. T., Chiu, H. M. et al., Plasma insulin-like growth factor-binding protein-2 levels as diagnostic and prognostic biomarker of colorectal cancer. J. Clin. Endocrinol. Metab. 2010, 95, 1717-1725.
100. Walker, G., MacLeod, K., Williams, A. R., Cameron, D. A. et al., Insulin-like growth factor binding proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine responsiveness in patients with ovarian cancer. Clin. Cancer Res. 2007, 13, 1438-1444.
101. Cai, W., Niu, G., Chen, X., Imaging of integrins as biomarkers for tumor angiogenesis. Curr. Pharm. Des. 2008, 14, 2943-2973.
102. Bhardwaj, A., Januzzi, J. L., Jr., ST2: A novel biomarker for heart failure. Expert Rev. Mol. Diagn. 2010, 10, 459-464.
103. Abdul-Salam, V. B., Ramrakha, P., Krishnan, U., Owen, D. R. et al., Identification and assessment of plasma lysozyme as a putative biomarker of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2010, 30, 1027-1033.
104. Chrysohoou, C., Pitsavos, C., Barbetseas, J., Kotroyiannis, I. et al., Chronic systemic inflammation accompanies impaired ventricular diastolic function, detected by Doppler imaging, in patients with newly diagnosed systolic heart failure (Hellenic Heart Failure Study). Heart Vessels 2009, 24, 22-26.
105. Cheng, H. L., Huang, H. J., Ou, B. Y., Chow, N. H. et al., Urinary CD14 as a potential biomarker for benign prostatic hyperplasia - discovery by combining MALDI-TOF-based biostatistics and ESI-MS/MS-based stable-isotope labeling. Proteomics Clin. Appl. 2011, 5, 121-132.
106. Albrethsen, J., Moller, C. H., Olsen, J., Raskov, H. et al., Human neutrophil peptides 1, 2 and 3 are biochemical markers for metastatic colorectal cancer. Eur. J. Cancer 2006, 42, 3057-3064.
107. Soejima, H., Irie, A., Fukunaga, T., Oe, Y. et al., Osteopontin expression of circulating T cells and plasma osteopontin levels are increased in relation to severity of heart failure. Circ. J. 2007, 71, 1879-1884.
108. Yatsuya, H., tamakoshi, K., Hattori, H., Otsuka, R. et al., Serum phospholipid transfer protein mass as a possible protective factor for coronary heart diseases. Circ. J. 2004, 68, 11-16.
109. Shi, L., Zhang, J., Wu, P., Feng, K. et al., Discovery and identification of potential biomarkers of pediatric acute lymphoblastic leukemia. Proteome Sci. 2009, 7, 7.
110. Korovesis, S., Fredericks, S., Holt, D., Toutouzas, P. et al., Release of platelet activation markers during coronary angioplasty. Coron. Artery Dis. 2000, 11, 391-398.
111. Jou, Y. J., Lin, C. D., Lai, C. H., Chen, C. H. et al., Proteomic identification of salivary transferrin as a biomarker for early detection of oral cancer. Anal Chim Acta 2010, 681, 41-48.
112. Hagg, D. A., Olson, F. J., Kjelldahl, J., Jernas, M. et al., Expression of chemokine (C-C motif) ligand 18 in human macrophages and atherosclerotic plaques. Atherosclerosis 2009, 204, e15-e20.
113. Schrottner, P., Wollner, S., Catusse, J., Burger, M., Detection of elevated serum levels of the chemokine CCL18 in B-cell chronic lymphocytic leukaemia: Identification of a novel biomarker. Acta Haematol. 2010, 124, 110-114.
114. Niu, J., Kolattukudy, P. E., Role of MCP-1 in cardiovascular disease: molecular mechanisms and clinical implications. Clin. Sci. (Lond) 2009, 117, 95-109.
115. Macoska, J. A., Begley, L. A., Dunn, R. L., Siddiqui, J. et al., Pilot and feasibility study of serum chemokines as markers to distinguish prostatic disease in men with low total serum PSA. Prostate 2008, 68, 442-452.
116. Tohmiya, Y., Koide, Y., Fujimaki, S., Harigae, H. et al., Stanniocalcin-1 as a novel marker to detect minimal residual disease of human leukemia. Tohoku J. Exp. Med. 2004, 204, 125-133.
117. Leja, J., Essaghir, A., Essand, M., Wester, K. et al., Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas. Mod. Pathol. 2009, 22, 261-272.
118. Glockner, S. C., Dhir, M., Yi, J. M., McGarvey, K. E. et al., Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res. 2009, 69, 4691-4699.
119. Prost, A. C., Menegaux, F., Langlois, P., Vidal, J. M. et al., Differential transferrin receptor density in human colorectal cancer: a potential probe for diagnosis and therapy. Int. J. Oncol. 1998, 13, 871-875.